Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1Other hematologic neoplasm 1Breast 1

Conditions

Glioblastoma 380Brain Neoplasms 376Glioma 232Gliosarcoma 147Astrocytoma 138Neuroblastoma 121Central Nervous System Neoplasms 118Oligodendroglioma 80Medulloblastoma 61Breast Neoplasms 52Neoplasms 51Melanoma 45Ependymoma 43Carcinoma, Non-Small-Cell Lung 42Recurrence 40Sarcoma 33Meningioma 33Rhabdomyosarcoma 32Osteosarcoma 31Neurofibromatosis 1 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 27Wilms Tumor 26Lung Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Sarcoma, Ewing 23Lymphoma 22Rhabdoid Tumor 20Hepatoblastoma 19Testicular Neoplasms 17

Interventions

sapanisertib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Meningeal Neoplasms × CNS × Clear all
NCT04250545 2026-05-26

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled 14 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

NCT01596127 2018-05-24

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 7 charts
CNSOther hematologic neoplasm

Central Nervous System Diseases, Leukemia, Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡